Shares of Chemed Co. (NYSE:CHE) have received an average recommendation of “Buy” from the five research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $332.00.
CHE has been the topic of several research reports. Zacks Investment Research downgraded shares of Chemed from a “buy” rating to a “hold” rating in a report on Tuesday, September 25th. Bank of America initiated coverage on shares of Chemed in a report on Friday, October 12th. They issued a “buy” rating and a $390.00 price target on the stock.
In other Chemed news, insider David Patrick Williams sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The stock was sold at an average price of $302.30, for a total value of $3,023,000.00. Following the sale, the insider now owns 24,918 shares in the company, valued at approximately $7,532,711.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kevin J. Mcnamara sold 7,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The stock was sold at an average price of $305.98, for a total value of $2,141,860.00. Following the completion of the sale, the insider now owns 141,293 shares in the company, valued at approximately $43,232,832.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,953 shares of company stock worth $7,678,463. Insiders own 4.90% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Fort L.P. purchased a new stake in Chemed in the 2nd quarter worth approximately $120,000. Rehmann Capital Advisory Group boosted its position in Chemed by 33,227.1% in the 3rd quarter. Rehmann Capital Advisory Group now owns 46,658 shares of the company’s stock worth $146,000 after purchasing an additional 46,518 shares in the last quarter. Cerebellum GP LLC purchased a new stake in Chemed in the 3rd quarter worth approximately $148,000. Tower Research Capital LLC TRC boosted its position in Chemed by 70.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 544 shares of the company’s stock worth $175,000 after purchasing an additional 224 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new stake in Chemed in the 3rd quarter worth approximately $225,000. Institutional investors and hedge funds own 88.06% of the company’s stock.
Shares of NYSE:CHE opened at $302.95 on Friday. Chemed has a twelve month low of $234.00 and a twelve month high of $335.99. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.11 and a current ratio of 1.14. The company has a market capitalization of $4.85 billion, a P/E ratio of 56.52, a price-to-earnings-growth ratio of 2.66 and a beta of 1.18.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Monday, October 29th. The company reported $3.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.80 by $0.27. Chemed had a net margin of 11.73% and a return on equity of 35.13%. The company had revenue of $444.15 million for the quarter, compared to the consensus estimate of $445.16 million. During the same quarter in the prior year, the company earned $2.15 EPS. Chemed’s quarterly revenue was up 6.4% on a year-over-year basis. On average, analysts forecast that Chemed will post 11.41 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Monday, November 12th were given a $0.30 dividend. The ex-dividend date was Thursday, November 8th. This represents a $1.20 annualized dividend and a yield of 0.40%. Chemed’s dividend payout ratio is presently 22.39%.
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
See Also: How to Invest in Growth Stocks
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.